Novo Nordisk's TBL Quarterly magazine tells the stories of the individuals that are making a difference for people living with diabetes.
Submitted by: Novo Nordisk
Posted: Nov 21, 2013 – 01:05 PM EST
NOVO ALLE, Denmark, Nov. 21 /CSRwire/ - The recent estimate from the International Diabetes Federation (IDF) Diabetes Atlas shows that globally 382 million people have diabetes, a figure that is equal to the combined population of the United States and United Kingdom. People living with diabetes in low- and middle-income countries make up 80% of the total global disease prevalence and many ethnic groups and rural communities do not receive necessary care and access to treatment.
Novo Nordisk’s latest issue of the TBL Quarterly tells the stories of how individuals and coordinated efforts are making a difference in communities and low-income countries to improve availability and access to diabetes care.
Novo Nordisk’s TBL Quarterly is available as a downloadable Adobe PDF. Click here to explore.
Leading change from South Dakota to Guinea
The latest issue of the TBL Quarterly introduces some of the programmes and people who are driving change to improve the prevention and treatment of diabetes.
The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to firstname.lastname@example.org.
About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both stakeholders and shareholders. Published following the company’s quarterly results, Novo Nordisk’s TBL Quarterly offers articles, photos and infographics that demonstrate how responsibility supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance. In 2013, Novo Nordisk received the Pharmaceuticals and Biotechnology industry group top ranking on Corporate Knight’s list of Global 100 Most Sustainable Corporations.
 International Diabetes Federation. The Diabetes Atlas. Sixth Edition. 2013